List of Excipients in Branded Drug DYNA-HEX 2

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	DYNA-HEX 2	chlorhexidine gluconate 2%	0116-1022	CITRIC ACID MONOHYDRATE
Xttrium Laboratories Inc	DYNA-HEX 2	chlorhexidine gluconate 2%	0116-1022	COCO DIETHANOLAMIDE
Xttrium Laboratories Inc	DYNA-HEX 2	chlorhexidine gluconate 2%	0116-1022	HYDROXYETHYL CELLULOSE
Xttrium Laboratories Inc	DYNA-HEX 2	chlorhexidine gluconate 2%	0116-1022	ISOPROPYL ALCOHOL
Xttrium Laboratories Inc	DYNA-HEX 2	chlorhexidine gluconate 2%	0116-1022	LAURAMINE OXIDE

DYNA-HEX 2 Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

DYNA-HEX 2 is a topical antiseptic built around chlorhexidine gluconate 2% and isopropyl alcohol 70%. Its commercial value comes from rapid antimicrobial action, persistent chlorhexidine activity, and use in clinical skin preparation. The formulation opportunity is not a new active ingredient. It is improvement of tolerability, packaging, delivery format, residue control, microbial stability, and institutional workflow.

The principal commercial risk is regulatory and technical: excipients must preserve chlorhexidine activity, avoid precipitation or incompatibility, remain stable in a high-alcohol system, and satisfy topical-antiseptic labeling requirements. A differentiated product could compete through lower skin irritation, improved surgical usability, preoperative standardization, or specialty formats rather than through composition-of-matter exclusivity.

What is DYNA-HEX 2 and how does its formulation work?

DYNA-HEX 2 is a topical antiseptic containing chlorhexidine gluconate 2% and isopropyl alcohol 70% as its active ingredients. Public product labeling identifies the formulation as an antiseptic skin cleanser used before procedures and for reduction of bacteria on the skin.[1]

The two actives perform different functions:

Component	Function	Commercial implication
Chlorhexidine gluconate 2%	Broad antimicrobial activity with residual effect on skin	Supports persistent protection and clinical differentiation
Isopropyl alcohol 70%	Rapid microbial kill through protein denaturation and membrane disruption	Supports fast drying and immediate activity
Water and other formulation components	Solubilization, viscosity, skin feel, color, fragrance, and processing	Create the main reformulation and product-differentiation opportunities

Alcohol concentration is critical. Lowering alcohol may reduce drying speed and immediate antimicrobial performance. Increasing alcohol can increase flammability, skin dryness, and compatibility risks with packaging and applicator materials.

Chlorhexidine is cationic. It can interact with anionic excipients, some polymers, soaps, surfactants, and textile treatments. The formulation must avoid loss of free chlorhexidine, precipitation, adsorption to packaging, or reduced bioavailability at the skin surface.

What excipients are strategically important in DYNA-HEX 2?

The highest-value excipient decisions relate to skin tolerability, chlorhexidine compatibility, evaporation, and delivery.

Solvent and water system

A high-purity water phase is required to dissolve chlorhexidine gluconate and control the final concentration. Water quality affects pH, ionic strength, microbial control, and long-term stability.

The target system must balance:

• Chlorhexidine solubility
• Alcohol-water phase behavior
• Skin wetting
• Drying time
• Residual antimicrobial activity
• Package compatibility

A lower-water system may dry faster but can worsen skin dryness and make dosing less uniform. A higher-water system may improve wetting but extend drying time and increase the risk of microbial or physical instability if the container closure is inadequate.

Humectants and emollients

Glycerin, propylene glycol, and selected polyols are common candidates for reducing skin dryness. Their use in a 70% alcohol product requires careful control because they can:

• Slow drying
• Increase tack or residue
• Alter wetting and spreading
• Change the perceived dose
• Affect applicator saturation
• Influence chlorhexidine release from wipes or sponge substrates

The strongest commercial opportunity is a low-residue emollient system that improves tolerability without undermining rapid drying. A formulation marketed for repeated clinical use must be evaluated against plain alcohol and standard chlorhexidine products using validated irritation and user-preference methods.

Surfactants and solubilizers

Surfactants can improve skin coverage and reduce beading on hydrophobic skin surfaces. They also create one of the largest technical risks.

Anionic surfactants are generally poor candidates because chlorhexidine can form insoluble or inactive complexes with anionic materials. Nonionic surfactants may be more suitable, but each candidate requires testing for:

• Chlorhexidine assay and degradation
• Antimicrobial effectiveness
• Precipitate formation
• Foam generation
• Skin residue
• Compatibility with polypropylene, polyethylene, PET, elastomers, and adhesives

A low-foam nonionic system could support a differentiated pump spray or applicator. The product should not rely on surfactant foam as evidence of cleaning or antimicrobial performance.

pH modifiers and buffers

Chlorhexidine formulations are sensitive to pH and ionic conditions. A buffer may improve batch consistency, but excessive ionic strength can affect solubility and activity. A lightly buffered or minimally buffered system may be preferable if stability data support it.

The formulation target should prioritize:

1. Chlorhexidine chemical stability.
2. Absence of visible precipitation.
3. Consistent skin deposition.
4. Acceptable irritation profile.
5. Compatibility with the alcohol-water vehicle.

Fragrance and dyes

Fragrance creates a weak commercial benefit and a meaningful tolerability risk. Fragrance-free positioning is more defensible for surgical, neonatal, intensive-care, and sensitive-skin applications.

Colorants can support product identification and dosing visibility, but they may create:

• Allergy or sensitivity concerns
• Textile staining
• Compatibility issues
• Regulatory labeling obligations
• Perceived residue on skin

A clear or lightly colored formulation could be positioned for surgical settings where staining is undesirable. Where color is retained, the colorant should be selected for low extractables, low adsorption, and stability in alcohol.

What formulation patents could protect a DYNA-HEX 2 follow-on product?

A conventional chlorhexidine 2% and alcohol 70% composition is unlikely to support strong composition-of-matter protection by itself. The defensible intellectual-property strategy would focus on formulation, delivery, packaging, and use claims.

Potential claim categories include:

Claim area	Potential subject matter	Relative IP value
Excipient system	Specific nonionic solubilizer, humectant, or low-residue emollient combination compatible with CHG and 70% alcohol	Moderate if supported by unexpected stability or tolerability
Delivery system	Metered applicator, prefilled sponge, wipe, spray, or foaming dispenser	Moderate to strong depending on structure
Drying control	Composition or package that reaches a defined dry-time range while maintaining antimicrobial performance	Moderate
Skin tolerability	Reduced irritation or improved barrier recovery with defined excipient concentrations	Moderate, but evidence-intensive
Packaging	Low-sorption container, closure, valve, or applicator compatible with CHG and alcohol	Moderate
Method of use	Procedure-specific preparation, dose, contact time, or repeat-use protocol	Narrow and potentially vulnerable
Manufacturing	Order of addition, mixing conditions, filtration, filling, or substrate impregnation process	Narrow to moderate

A patent search should cover chlorhexidine gluconate, alcohol-based antiseptics, surgical skin preparation, preoperative applicators, antimicrobial wipes, CHG-compatible polymers, and low-irritation formulations. Relevant jurisdictions are the United States, Europe, Japan, China, Canada, Australia, and major hospital-procurement markets.

The product itself should not be assumed to have an Orange Book-listed patent estate. Orange Book listing generally concerns approved drug applications and patents submitted by NDA holders. A topical antiseptic marketed under an OTC pathway or monograph framework may not have Orange Book protection comparable to an NDA product.[2]

When does DYNA-HEX 2 lose exclusivity?

DYNA-HEX 2 does not appear to have a conventional small-molecule exclusivity profile comparable to an innovative prescription drug. Chlorhexidine and isopropyl alcohol are established antiseptic actives, and competing products may enter through applicable OTC regulatory pathways, private-label arrangements, or alternative drug applications.

The relevant commercial barriers are likely to be:

• Regulatory compliance
• Manufacturing validation
• Antimicrobial performance
• Flammability controls
• Packaging qualification
• Hospital formulary adoption
• Procurement contracts
• Brand recognition
• Product liability and safety records

A product-specific patent expiration date cannot be treated as the principal market-entry date without confirmation of an issued patent tied to DYNA-HEX 2 or its manufacturer. The principal competitive threat is likely formulation and private-label substitution rather than a classic Paragraph IV generic launch.

What is the FDA regulatory status of DYNA-HEX 2?

DYNA-HEX 2 is a topical antiseptic product marketed for healthcare skin cleansing. FDA regulation of topical antiseptics has evolved through the OTC monograph system, final rules, administrative orders, and product-specific applications. The applicable pathway depends on the exact claims, active ingredients, dosage form, labeling, and marketing history.[2][3]

The regulatory analysis should distinguish among:

• Healthcare antiseptic claims
• Consumer antiseptic wash claims
• Preoperative skin-preparation claims
• Patient pre-injection cleansing
• Surgical-site preparation
• Hand antisepsis
• Wound cleansing

Claims outside the established labeling framework can trigger a different regulatory pathway. A reformulated product should preserve the approved or permitted indication set unless the sponsor is prepared to support a new regulatory submission.

What FDA data matter for a reformulated product?

A commercial reformulation would typically require evidence addressing:

• Active ingredient identity and assay
• Chlorhexidine content over shelf life
• Alcohol concentration
• Antimicrobial effectiveness
• Microbial limits
• Preservative or container-closure performance where applicable
• Skin irritation and sensitization
• Flammability
• Extractables and leachables
• Package integrity
• Applicator dose uniformity
• Drying time
• Residual activity

Chlorhexidine hypersensitivity is a known safety concern and has been addressed in FDA safety communications. A lower-irritation formulation does not eliminate the need for prominent chlorhexidine warnings and controlled clinical-use labeling.[4]

What commercial opportunities exist for DYNA-HEX 2 excipient innovation?

Surgical and procedural applicators

The strongest opportunity is a prefilled, standardized applicator that delivers a reproducible amount of 2% chlorhexidine in 70% alcohol. Hospitals value predictable coverage, reduced preparation time, lower contamination risk, and simplified staff training.

Potential formats include:

• Single-use sponge applicators
• Large-area applicators for orthopedic and cardiac procedures
• Small applicators for catheter insertion
• Metered sprays
• Low-drip vertical applicators
• Sterile procedure kits

The formulation should be optimized for substrate retention, controlled release, rapid drying, and minimal pooling.

Sensitive-skin and repeated-use products

A fragrance-free, low-residue formulation with a validated skin-tolerability advantage could target intensive-care units, dialysis, catheter care, and repeated procedural preparation. The commercial claim should rely on measured irritation, dryness, and barrier-recovery outcomes rather than subjective marketing language.

Pediatric and neonatal settings

Neonatal use requires a separate safety and regulatory assessment. The opportunity is real because neonatal and pediatric skin has different barrier characteristics, but an adult formulation should not be repositioned for these populations without dedicated evidence.

Private-label and institutional supply

The established active ingredients support contract manufacturing and private-label supply. Hospitals, group purchasing organizations, ambulatory surgery centers, and procedure-kit companies may prefer a qualified alternative to branded antiseptics if the product offers:

• Lower acquisition cost
• Reliable supply
• Compatible applicator formats
• Simplified storage
• Contract-specific packaging
• Consistent lot release

International markets

Geographic expansion requires country-specific review of antiseptic classification, permissible claims, alcohol handling, language requirements, and clinical-use standards. In Europe, antiseptic products may fall under the Biocidal Products Regulation depending on the claimed use. Other jurisdictions may regulate the product as a medicine, medical device, or combination product.

Which companies and product categories challenge DYNA-HEX 2?

The competitive set includes:

Competitor category	Examples	Competitive basis
CHG-alcohol products	ChloraPrep and comparable products	Standardized applicators, procedure integration, clinical familiarity
CHG aqueous products	Hibiclens and comparable washes	Consumer and healthcare cleansing, lower alcohol exposure
Povidone-iodine	Betadine and institutional alternatives	Broad antiseptic use and established procurement
Alcohol-only products	Ethanol or isopropyl alcohol preparations	Low cost and rapid drying
CHG cloths and wipes	Impregnated bathing and preparation products	Workflow convenience and repeat-use applications
Private-label antiseptics	Hospital and distributor brands	Price, supply, and contract flexibility

DYNA-HEX 2 can compete most effectively where the buyer values chlorhexidine persistence but wants a lower-cost or more flexible format than premium branded applicators.

What generic entry risks exist for DYNA-HEX 2?

The generic-entry risk is high at the active-ingredient level because chlorhexidine and isopropyl alcohol are established substances. The product-level risk is moderated by manufacturing controls and procurement barriers.

A competitor can reproduce the basic active profile, but commercial substitution still requires:

• Demonstrated antimicrobial performance
• Reliable alcohol concentration
• Stable chlorhexidine assay
• Suitable packaging
• Flammability compliance
• Hospital approval
• Product liability review
• Distribution access

Paragraph IV litigation is not the central risk unless DYNA-HEX 2 or a related product is supported by an Orange Book-listed NDA patent. A competitor seeking to enter with the same active ingredients would more likely pursue an OTC or other applicable regulatory route than challenge a conventional prescription-drug patent.

How strong is the patent estate for a DYNA-HEX 2 reformulation?

The baseline patent estate is likely weak if limited to chlorhexidine gluconate 2% in 70% isopropyl alcohol. A stronger estate would require measurable technical differentiation.

The best targets are:

1. A defined excipient combination that improves skin tolerability without reducing antimicrobial activity.
2. A delivery system that controls dose and coverage.
3. A CHG-compatible applicator or wipe substrate.
4. A packaging system that reduces active loss and extractables.
5. A manufacturing process that improves uniformity or shelf life.
6. A procedure-specific use supported by clinical or operational data.

Patent strength will depend on whether the improvement is unexpected, reproducible, and difficult to design around. Trade-secret protection may be more practical for mixing order, substrate impregnation, filling parameters, and quality-control specifications.

What licensing and partnership opportunities exist?

Potential partners include:

• Hospital supply distributors
• Procedure-kit manufacturers
• Contract pharmaceutical manufacturers
• Surgical applicator companies
• Group purchasing organizations
• International antiseptic-product licensees
• Packaging companies with alcohol-resistant dispensing systems

The most attractive licensing package would combine the formulation, applicator design, stability data, and regulatory file. Licensing only the active composition would offer limited defensibility because the actives are widely available.

Key Takeaways

• DYNA-HEX 2 is based on chlorhexidine gluconate 2% and isopropyl alcohol 70%.
• The main excipient opportunity is improved skin tolerability without reducing antimicrobial activity or delaying dry time.
• Anionic excipients and incompatible polymers create significant chlorhexidine interaction risks.
• Fragrance-free, low-residue, and applicator-integrated products offer the clearest differentiation.
• A basic chlorhexidine-alcohol composition is unlikely to provide strong patent protection.
• Formulation, delivery, packaging, manufacturing, and procedure-specific claims are more viable IP targets.
• Orange Book and Paragraph IV analysis should not be assumed to apply unless a qualifying NDA and listed patents are confirmed.
• Hospital procurement, applicator standardization, supply reliability, and private-label economics may matter more than patent exclusivity.
• The most commercially attractive development path is a validated single-use applicator or low-irritation formulation supported by stability, antimicrobial, skin-tolerability, and workflow data.

FAQs

Can DYNA-HEX 2 be reformulated without changing its regulatory category?

Possibly, if the reformulation preserves the applicable active ingredients, concentrations, dosage form, labeling, and permitted claims. Material changes to claims, delivery system, or patient population can alter the regulatory pathway.

Is chlorhexidine compatible with glycerin?

Compatibility is formulation-specific. Glycerin may improve skin feel, but the sponsor must confirm chlorhexidine assay, physical stability, antimicrobial performance, drying time, and residue in the final alcohol-water system.

Can a new DYNA-HEX 2 product claim superior skin tolerability?

Only with appropriate comparative evidence. A defensible claim would require controlled irritation, dryness, sensitization, and barrier-recovery data against a relevant comparator.

Are chlorhexidine antiseptic products eligible for biosimilar competition?

No. Biosimilar regulation applies to biological products. DYNA-HEX 2 is a small-molecule topical antiseptic product, so competition would involve generics, OTC products, private-label products, or alternative antiseptic formulations.

What is the most valuable patent claim for a DYNA-HEX 2 competitor?

A claim covering a specific CHG-compatible excipient system combined with a standardized applicator and demonstrated improvements in stability, skin tolerability, dose uniformity, or drying performance is likely more valuable than a broad claim to chlorhexidine in alcohol.

References

1. DailyMed. (n.d.). DYNA-HEX 2 chlorhexidine gluconate 2% solution product labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2021). OTC Monograph M003: Topical antiseptic drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2019). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 84 Fed. Reg. 14849.

4. U.S. Food and Drug Administration. (2017). FDA warns about rare but serious allergic reactions with chlorhexidine gluconate. FDA Drug Safety Communication.

5. U.S. Centers for Disease Control and Prevention. (2017). Guideline for the prevention of surgical site infection. CDC.